indications for glp 1 agonists GI Adverse Effects of Glucagon-Like Peptide-1 Receptor The Role of Glucagon-Like Peptide-1
Description
Background Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are a class of medications initially developed to treat type 2 diabetes (T2D) and obesity
doi: 10.1016/j.tips.2022.11.001
Starting at the lowest dose and increasing the dose gradually over time may help to minimize side effects
As mentioned above, tirzepatide hasnt been compared to the higher dose of semaglutide (Wegovy) now available
When ASCVD predominates: ASCVD is considered to predominate if a patient has established ASCVD or if they have indicators of high ASCVD risk
PubMed, de Graaf, Chris, et al
